BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the most promising biotech stocks to buy according to hedge funds. Analysts at Piper Sandler have reaffirmed their ‘Overweight’ rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) with an unchanged price target of $68, implying an upside potential of nearly 33%. This confidence is driven by the company’s unique efficacy profile that strengthens its launch dynamics. During the conversation with the research firm’s team, management revealed that third-quarter perform ...